Shares of Corbus Pharmaceuticals Holdings Inc. CRBP slipped 5.31% to $14.28 Monday, on what proved to be an all-around mixed ...

Corbus Pharmaceuticals Holdings Inc. closed $46.82 short of its 52-week high ($61.90), which the company achieved on July ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating on December 2.Pick the best ...

MetLife Investment Management LLC bought a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the ...

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD ...

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time ...

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this ...

Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer.

Piper Sandler started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research note released on ...

Piper Sandler has initiated coverage of Corbus Pharmaceuticals (NASDAQ:CRBP) and Viking Therapeutics (NASDAQ:VKTX) with overweight ratings. The investment bank said it believes Corbus’s (CRBP ...